Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
Conditions:   Nasopharyngeal Carcinoma;   Castrate Resistant Prostate Cancer;   Gastric Cancer;   Ovarian Clear Cell Carcinoma;   Mesothelioma;   Sarcoma;   Non Hodgkin Lymphoma;   B Cell Lymphoma;   Epithelioid Sarcoma Intervention:   Drug: APG-5918 Sponsor:   Ascentage Pharma Group Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 10, 2022 Category: Research Source Type: clinical trials